Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.
Laurus Labs operates in four business lines:
- Generics active pharmaceutical ingredients (APIs) – The development, manufacture and sale of APIs and advanced intermediates.
- Generics finished dosage forms (FDFs) – The development and manufacture of oral solid formulations.
- Synthesis – Contract development and manufacturing services for global pharmaceutical companies.
- Ingredients – The manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors.
Key Highlights: - Laurus Labs launched 59 products since our inception in 2005.
- Nine out of the 10 largest generic pharmaceutical companies in the world are its customers.
- Laurus Labs employed 587 scientists at our R&D center in Hyderabad and 12 scientists at R&D centre in Greater Boston USA.
- The Company owned 32 patents and had 150 pending patent applications, in several countries.
- Company has three manufacturing facilities in Visakhapatnam, Andhra Pradesh.
- Company sells its products in 32 countries in Sub-Saharan Africa, South-East Asia and Latin America.
Key Strengths: - Leadership in APIs in Select, High Growth Therapeutic Areas
- Strong R&D Capabilities and Process Chemistry Skills
- Industry Leading, Modern and Regulatory Compliant Manufacturing Capacities
- Long-standing Relationships with Multi-National Pharmaceutical Companies
- Experienced Promoters and Qualified Operational Personnel
- Established Track Record of Delivering Growth
Laurus Labs IPO Details
| Issue Type | Book Built Issue IPO |
| Face Value | ₹10 per equity share |
| IPO Price | ₹426 to ₹428 per equity share |
| Market Lot | 35 Shares |
| Min Order Quantity | 35 Shares |
| Listing At | BSE, NSE |
| BSE Script Code | 540222 |
| NSE Symbol | LAURUSLABS |
| ISIN | INE947Q01010 |
| Issue Size | Aggregating up to ₹1,331.80 Cr |
| Fresh Issue | Aggregating up to ₹300.00 Cr |
| Offer for Sale | Aggregating up to ₹1,031.80 Cr |
Laurus Labs IPO Tentative Timetable
| PARTICULAR | DATE |
| IPO Open Date | 6-Dec-16 |
| IPO Close Date | 8-Dec-16 |
| Basis of Allotment Date | 14-Dec-16 |
| IPO Listing Date | 19-Dec-16 |
Laurus Labs IPO Lot Size
| Application | Lots | Shares | Amount (Cut-off) |
| Minimum | 1 | 35 | ₹14,980 |
| Maximum | 13 | 455 | ₹194,740 |
IPO Allotment Status
Please Click Hare To Check IPO Allotment Status For Laurus Labs Ltd
Company Promoters:
The Promoters of the company are:
- Dr Satyanarayana Chava
- Naga Rani Chava
- Dr Raju Srihari Kalidindi
- Ravi Kumar V V and
- Dr Lakshmana Rao C V
Company Financials:
| PARTICULAR | 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 |
| Total Assets | 23,083.48 | 18,925.49 | 12,730.58 | 7,009.89 | 5,128.78 |
| Total Revenue | 17,884.15 | 13,603.80 | 11,685.34 | 7,235.67 | 4,523.07 |
| Profit After Tax (PAT) | 1,435.68 | 735.17 | 972.17 | 882.19 | 215.77 |
Objects of the Issue:
The object of the issue are to:
- Pre-payment of term loans; and
- General corporate purposes.
Registrar & Company Details
| Company Contact Information | Laurus Labs IPO Registrar |
| Laurus Labs Ltd Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021 Phone: + 91 40 3980 4333 Email: secretarial@lauruslabs.com Website: http://www.lauruslabs.com | KFintech Private Limited Selenium Building, Tower-B, Plot No 31 & 32, Financial District,Nanakramguda, Serilingampally, Rangareddi, Telangana India – 500 032. Phone: 1-800-3454001 Email: einward.ris@karvy.com Website: https://karisma.kfintech.com/ |
